Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657410 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4TGFBR1 | |
| SCHEMBL3065693 | 0.86 | CHRNB2 (0.89) | CHRNB2CHRNA4TGFBR1 | |
| SCHEMBL4828801 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4PIK3CGSUV39H2 | |
| SCHEMBL4828980 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4PIK3CGSUV39H2 | |
| SCHEMBL4824715 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4PIK3CGSUV39H2 | |
| SCHEMBL4822146 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4PIK3CGSUV39H2 | |
| SCHEMBL6351766 | 0.78 | CHRNB2 (0.54) | CHRNB2CHRNA4SMN1; SMN2SUV39H2 | |
| SCHEMBL5090919 | 0.77 | CHRNB2 (0.50) | CHRNB2CHRNA4PIK3CGALDH1A1 | |
| SCHEMBL25188188 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4ALDH1A1LMNATGFBR1 | |
| SCHEMBL29833760 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4ALDH1A1LMNATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003500402-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1178982-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071534-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2000-11-30 | — | — | WO | claimed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | CHRNB2 16/4885CHRNA4 12/4885PIK3CG 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.